Active 0 6 0 6 O
autoimmune 7 17 7 17 B-chronic_disease
disease 18 25 18 25 I-chronic_disease
that 26 30 26 30 O
has 31 34 31 34 O
required 35 43 35 43 O
systemic 44 52 44 52 B-treatment
treatment 53 62 53 62 I-treatment
in 63 65 63 65 O
past 66 70 66 70 B-upper_bound
2 71 72 71 72 I-upper_bound
years 73 78 73 78 I-upper_bound
( 79 80 79 80 O
i.e. 80 84 80 84 O
with 85 89 85 89 O
use 90 93 90 93 O
of 94 96 94 96 O
disease 97 104 97 104 O
modifying 105 114 105 114 O
agents 115 121 115 121 O
, 121 122 121 122 O
corticosteroids 123 138 123 138 B-treatment
or 139 141 139 141 O
immunosuppressive 142 159 142 159 B-treatment
drugs 160 165 160 165 I-treatment
) 165 166 165 166 O

Active 0 6 167 173 O
, 6 7 173 174 O
uncontrolled 8 20 175 187 O
bacterial 21 30 188 197 B-chronic_disease
, 30 31 197 198 O
viral 32 37 199 204 B-chronic_disease
, 37 38 204 205 O
or 39 41 206 208 O
fungal 42 48 209 215 B-chronic_disease
infections 49 59 216 226 I-chronic_disease
, 59 60 226 227 O
within 61 67 228 234 O
7 68 69 235 236 B-upper_bound
days 70 74 237 241 I-upper_bound
of 75 77 242 244 O
study 78 83 245 250 O
entry 84 89 251 256 O
requiring 90 99 257 266 O
systemic 100 108 267 275 B-treatment
therapy 109 116 276 283 I-treatment

Clinically 0 10 284 294 O
significant 11 22 295 306 O
peripheral 23 33 307 317 B-chronic_disease
neuropathy 34 44 318 328 I-chronic_disease
at 45 47 329 331 O
the 48 51 332 335 O
time 52 56 336 340 O
of 57 59 341 343 O
study 60 65 344 349 O
entry 66 71 350 355 O

Clinically 0 10 356 366 O
- 10 11 366 367 O
significant 11 22 367 378 O
gastrointestinal 23 39 379 395 B-chronic_disease
disorders 40 49 396 405 I-chronic_disease
, 49 50 405 406 O
such 51 55 407 411 O
as 56 58 412 414 O
perforation 59 70 415 426 B-chronic_disease
, 70 71 426 427 O
gastrointestinal 72 88 428 444 B-chronic_disease
bleeding 89 97 445 453 I-chronic_disease
, 97 98 453 454 O
or 99 101 455 457 O
diverticulitis 102 116 458 472 B-chronic_disease

Disease 0 7 473 480 O
- 7 8 480 481 O
free 8 12 481 485 O
of 13 15 486 488 O
active 16 22 489 495 O
second 23 29 496 502 O
/ 29 30 502 503 O
secondary 30 39 503 512 O
or 40 42 513 515 O
prior 43 48 516 521 O
malignancies 49 61 522 534 B-cancer
for 62 65 535 538 O
equal 66 71 539 544 O
to 72 74 545 547 O
or 75 77 548 550 O
over 78 82 551 555 O
2 83 84 556 557 B-lower_bound
years 85 90 558 563 I-lower_bound
with 91 95 564 568 O
the 96 99 569 572 O
exception 100 109 573 582 O
of 110 112 583 585 O
currently 113 122 586 595 O
treated 123 130 596 603 O
basal 131 136 604 609 B-cancer
cell 137 141 610 614 I-cancer
, 141 142 614 615 O
squamous 143 151 616 624 B-cancer
cell 152 156 625 629 I-cancer
carcinoma 157 166 630 639 I-cancer
of 167 169 640 642 O
the 170 173 643 646 O
skin 174 178 647 651 O
, 178 179 651 652 O
or 180 182 653 655 O
carcinoma 183 192 656 665 B-cancer
in 193 195 666 668 I-cancer
- 195 196 668 669 I-cancer
situ 196 200 669 673 I-cancer
of 201 203 674 676 O
the 204 207 677 680 O
cervix 208 214 681 687 O
or 215 217 688 690 O
breast 218 224 691 697 O

For 0 3 698 701 O
men 4 7 702 705 B-gender
and 8 11 706 709 O
women 12 17 710 715 B-gender
of 18 20 716 718 O
child 21 26 719 724 O
- 26 27 724 725 O
producing 27 36 725 734 O
potential 37 46 735 744 O
, 46 47 744 745 O
the 48 51 746 749 B-contraception_consent
use 52 55 750 753 I-contraception_consent
of 56 58 754 756 I-contraception_consent
effective 59 68 757 766 I-contraception_consent
contraceptive 69 82 767 780 I-contraception_consent
methods 83 90 781 788 I-contraception_consent
during 91 97 789 795 O
the 98 101 796 799 O
study 102 107 800 805 O
and 108 111 806 809 O
for 112 115 810 813 O
6 116 117 814 815 B-upper_bound
months 118 124 816 822 I-upper_bound
following 125 134 823 832 O
the 135 138 833 836 O
last 139 143 837 841 O
dose 144 148 842 846 O
of 149 151 847 849 O
study 152 157 850 855 O
drug 158 162 856 860 O

Fridericia 0 10 861 871 B-clinical_variable
- 10 11 871 872 I-clinical_variable
corrected 11 20 872 881 I-clinical_variable
QT 21 23 882 884 I-clinical_variable
interval 24 32 885 893 I-clinical_variable
( 33 34 894 895 I-clinical_variable
QTcF 34 38 895 899 I-clinical_variable
) 38 39 899 900 I-clinical_variable
> 40 41 901 902 O
470 42 45 903 906 B-lower_bound
msec 46 50 907 911 I-lower_bound
( 51 52 912 913 O
female 52 58 913 919 B-gender
) 58 59 919 920 O
or 60 62 921 923 O
> 63 64 924 925 O
450 65 68 926 929 B-lower_bound
( 69 70 930 931 O
male 70 74 931 935 O
) 74 75 935 936 O
, 75 76 936 937 O
or 77 79 938 940 O
history 80 87 941 948 O
of 88 90 949 951 O
congenital 91 101 952 962 B-chronic_disease
long 102 106 963 967 I-chronic_disease
QT 107 109 968 970 I-chronic_disease
syndrome 110 118 971 979 I-chronic_disease

History 0 7 980 987 O
of 8 10 988 990 O
( 11 12 991 992 O
non 12 15 992 995 O
- 15 16 995 996 O
infectious 16 26 996 1006 O
) 26 27 1006 1007 O
pneumonitis 28 39 1008 1019 B-chronic_disease
that 40 44 1020 1024 O
required 45 53 1025 1033 O
steroids 54 62 1034 1042 B-treatment
or 63 65 1043 1045 O
current 66 73 1046 1053 O
pneumonitis 74 85 1054 1065 O

History 0 7 1066 1073 O
of 8 10 1074 1076 O
interstitial 11 23 1077 1089 B-chronic_disease
lung 24 28 1090 1094 I-chronic_disease
disease 29 36 1095 1102 I-chronic_disease

History 0 7 1103 1110 O
of 8 10 1111 1113 O
known 11 16 1114 1119 O
or 17 19 1120 1122 O
suspected 20 29 1123 1132 O
autoimmune 30 40 1133 1143 B-chronic_disease
disease 41 48 1144 1151 I-chronic_disease
with 49 53 1152 1156 O
the 54 57 1157 1160 O
specific 58 66 1161 1169 O
exceptions 67 77 1170 1180 O
of 78 80 1181 1183 O
vitiligo 81 89 1184 1192 B-chronic_disease
, 89 90 1192 1193 O
atopic 91 97 1194 1200 B-chronic_disease
dermatitis 98 108 1201 1211 I-chronic_disease
, 108 109 1211 1212 O
or 110 112 1213 1215 O
psoriasis 113 122 1216 1225 B-chronic_disease
not 123 126 1226 1229 O
requiring 127 136 1230 1239 O
systemic 137 145 1240 1248 B-treatment
treatment 146 155 1249 1258 I-treatment

History 0 7 1259 1266 O
of 8 10 1267 1269 O
osteonecrosis 11 24 1270 1283 B-chronic_disease
of 25 27 1284 1286 I-chronic_disease
the 28 31 1287 1290 I-chronic_disease
hip 32 35 1291 1294 I-chronic_disease
or 36 38 1295 1297 O
have 39 43 1298 1302 O
evidence 44 52 1303 1311 O
of 53 55 1312 1314 O
structural 56 66 1315 1325 O
bone 67 71 1326 1330 O
abnormalities 72 85 1331 1344 O
in 86 88 1345 1347 O
the 89 92 1348 1351 O
proximal 93 101 1352 1360 O
femur 102 107 1361 1366 O
on 108 110 1367 1369 O
MRI 111 114 1370 1373 B-treatment
scan 115 119 1374 1378 I-treatment
that 120 124 1379 1383 O
are 125 128 1384 1387 O
symptomatic 129 140 1388 1399 O
and 141 144 1400 1403 O
clinically 145 155 1404 1414 O
significant 156 167 1415 1426 O

In 0 2 1427 1429 O
advanced 3 11 1430 1438 O
esophagogastric 12 27 1439 1454 B-cancer
malignancies 28 40 1455 1467 I-cancer

Intolerance 0 11 1468 1479 O
or 12 14 1480 1482 O
severe 15 21 1483 1489 O
hypersensitivity 22 38 1490 1506 O
( 39 40 1507 1508 O
≥Grade 40 46 1508 1514 O
3 47 48 1515 1516 I-lower_bound
) 48 49 1516 1517 O
to 50 52 1518 1520 O
pembrolizumab 53 66 1521 1534 B-allergy_name
and/or 67 73 1535 1541 O
of 74 76 1542 1544 O
its 77 80 1545 1548 O
excipients 81 91 1549 1559 B-allergy_name

Known 0 5 1560 1565 O
osteoblastic 6 18 1566 1578 B-cancer
bony 19 23 1579 1583 I-cancer
metastasis 24 34 1584 1594 I-cancer

Known 0 5 1595 1600 O
to 6 8 1601 1603 O
be 9 11 1604 1606 O
human 12 17 1607 1612 B-chronic_disease
immunodeficiency 18 34 1613 1629 I-chronic_disease
virus 35 40 1630 1635 I-chronic_disease
( 41 42 1636 1637 I-chronic_disease
HIV 42 45 1637 1640 I-chronic_disease
) 45 46 1640 1641 I-chronic_disease
positive 47 55 1642 1650 O
, 55 56 1650 1651 O
have 57 61 1652 1656 O
hepatitis 62 71 1657 1666 B-chronic_disease
B 72 73 1667 1668 I-chronic_disease
surface 74 81 1669 1676 O
antigen 82 89 1677 1684 O
( 90 91 1685 1686 O
HBSAg 91 96 1686 1691 O
) 96 97 1691 1692 O
, 97 98 1692 1693 O
or 99 101 1694 1696 O
hepatitis 102 111 1697 1706 B-chronic_disease
C 112 113 1707 1708 I-chronic_disease
antibodies 114 124 1709 1719 O
( 125 126 1720 1721 O
HCAb 126 130 1721 1725 O
) 130 131 1725 1726 O
unless 132 138 1727 1733 O
HCV 139 142 1734 1737 B-clinical_variable
RNA 143 146 1738 1741 I-clinical_variable
is 147 149 1742 1744 O
undetected 150 160 1745 1755 O
/ 160 161 1755 1756 O
negative 161 169 1756 1764 O

Must 0 4 1765 1769 O
be 5 7 1770 1772 O
≥18 8 11 1773 1776 O
years 12 17 1777 1782 I-lower_bound
of 18 20 1783 1785 O
age 21 24 1786 1789 B-age

Must 0 4 1790 1794 O
have 5 9 1795 1799 O
one 10 13 1800 1803 B-lower_bound
or 14 16 1804 1806 O
more 17 21 1807 1811 O
tumors 22 28 1812 1818 B-cancer
measurable 29 39 1819 1829 O
on 40 42 1830 1832 O
radiographic 43 55 1833 1845 O
imaging 56 63 1846 1853 O
as 64 66 1854 1856 O
defined 67 74 1857 1864 O
by 75 77 1865 1867 O
the 78 81 1868 1871 O
Response 82 90 1872 1880 O
Evaluation 91 101 1881 1891 O
Criteria 102 110 1892 1900 O
in 111 113 1901 1903 O
Solid 114 119 1904 1909 B-cancer
Tumors 120 126 1910 1916 I-cancer
( 127 128 1917 1918 O
RECIST 128 134 1918 1924 O
) 134 135 1924 1925 O
. 135 136 1925 1926 O
Patients 137 145 1927 1935 O
with 146 150 1936 1940 O
evaluable 151 160 1941 1950 O
but 161 164 1951 1954 O
not 165 168 1955 1958 O
measurable 169 179 1959 1969 O
disease 180 187 1970 1977 O
per 188 191 1978 1981 O
RECIST 192 198 1982 1988 O
criteria 199 207 1989 1997 O
may 208 211 1998 2001 O
be 212 214 2002 2004 O
enrolled 215 223 2005 2013 O
with 224 228 2014 2018 O
the 229 232 2019 2022 O
approval 233 241 2023 2031 O
of 242 244 2032 2034 O
the 245 248 2035 2038 O
medical 249 256 2039 2046 O
monitor 257 264 2047 2054 O

New 0 3 2055 2058 B-clinical_variable
York 4 8 2059 2063 I-clinical_variable
Heart 9 14 2064 2069 I-clinical_variable
Association 15 26 2070 2081 I-clinical_variable
Class 27 32 2082 2087 I-clinical_variable
III 33 36 2088 2091 B-lower_bound
or 37 39 2092 2094 O
IV 40 42 2095 2097 B-upper_bound
, 42 43 2097 2098 O
cardiac 44 51 2099 2106 B-chronic_disease
disease 52 59 2107 2114 I-chronic_disease
, 59 60 2114 2115 O
myocardial 61 71 2116 2126 B-chronic_disease
infarction 72 82 2127 2137 I-chronic_disease
within 83 89 2138 2144 O
the 90 93 2145 2148 O
past 94 98 2149 2153 B-upper_bound
6 99 100 2154 2155 I-upper_bound
months 101 107 2156 2162 I-upper_bound
, 107 108 2162 2163 O
unstable 109 117 2164 2172 O
arrhythmia 118 128 2173 2183 B-chronic_disease

Participants 0 12 2184 2196 O
must 13 17 2197 2201 O
be 18 20 2202 2204 O
refractory 21 31 2205 2215 O
or 32 34 2216 2218 O
intolerant 35 45 2219 2229 O
to 46 48 2230 2232 O
at 49 51 2233 2235 O
least 52 57 2236 2241 O
one 58 61 2242 2245 B-lower_bound
prior 62 67 2246 2251 B-treatment
therapy(ies 68 79 2252 2263 I-treatment
) 79 80 2263 2264 I-treatment
for 81 84 2265 2268 O
metastatic 85 95 2269 2279 B-cancer
or 96 98 2280 2282 I-cancer
locally 99 106 2283 2290 I-cancer
advanced 107 115 2291 2299 I-cancer
disease 116 123 2300 2307 I-cancer

Participants 0 12 2308 2320 O
who 13 16 2321 2324 O
have 17 21 2325 2329 O
a 22 23 2330 2331 O
history 24 31 2332 2339 O
of 32 34 2340 2342 O
hypersensitivity 35 51 2343 2359 O
reactions 52 61 2360 2369 O
to 62 64 2370 2372 O
TAXOL 65 70 2373 2378 B-allergy_name
® 70 71 2378 2379 O
or 72 74 2380 2382 O
other 75 80 2383 2388 O
drugs 81 86 2389 2394 O
formulated 87 97 2395 2405 O
in 98 100 2406 2408 O
Cremophor 101 110 2409 2418 B-allergy_name
® 110 111 2418 2419 O
EL 112 114 2420 2422 B-allergy_name
( 115 116 2423 2424 I-allergy_name
polyoxyethylated 116 132 2424 2440 I-allergy_name
castor 133 139 2441 2447 I-allergy_name
oil 140 143 2448 2451 I-allergy_name
) 143 144 2451 2452 I-allergy_name
. 144 145 2452 2453 O
Patients 146 154 2454 2462 O
who 155 158 2463 2466 O
exhibit 159 166 2467 2474 O
these 167 172 2475 2480 O
hypersensitivities 173 191 2481 2499 O
will 192 196 2500 2504 O
be 197 199 2505 2507 O
eligible 200 208 2508 2516 O
to 209 211 2517 2519 O
receive 212 219 2520 2527 O
single 220 226 2528 2534 O
agent 227 232 2535 2540 O
DKN-01 233 239 2541 2547 B-treatment

Participants 0 12 2548 2560 O
with 13 17 2561 2565 O
histologically 18 32 2566 2580 O
confirmed 33 42 2581 2590 O
recurrent 43 52 2591 2600 O
or 53 55 2601 2603 O
metastatic 56 66 2604 2614 B-cancer
esophageal 67 77 2615 2625 I-cancer
or 78 80 2626 2628 O
gastro 81 87 2629 2635 B-cancer
- 87 88 2635 2636 I-cancer
esophageal 88 98 2636 2646 I-cancer
junction 99 107 2647 2655 I-cancer
squamous 108 116 2656 2664 B-cancer
cell 117 121 2665 2669 I-cancer
or 122 124 2670 2672 O
adenocarcinoma 125 139 2673 2687 B-cancer
or 140 142 2688 2690 O
gastric 143 150 2691 2698 B-cancer
adenocarcinoma 151 165 2699 2713 I-cancer
with 166 170 2714 2718 O
Wnt 171 174 2719 2722 O
Signaling 175 184 2723 2732 O
Alterations 185 196 2733 2744 O

Patients 0 8 2745 2753 O
with 9 13 2754 2758 O
pre 14 17 2759 2762 O
- 17 18 2762 2763 O
existing 18 26 2763 2771 O
peripheral 27 37 2772 2782 B-chronic_disease
neuropathy 38 48 2783 2793 I-chronic_disease
will 49 53 2794 2798 O
be 54 56 2799 2801 O
allowed 57 64 2802 2809 O
to 65 67 2810 2812 O
receive 68 75 2813 2820 O
single 76 82 2821 2827 O
agent 83 88 2828 2833 O
DKN-01 89 95 2834 2840 O

Performance 0 11 2841 2852 B-clinical_variable
status 12 18 2853 2859 I-clinical_variable
of 19 21 2860 2862 O
0 22 23 2863 2864 B-lower_bound
or 24 26 2865 2867 O
1 27 28 2868 2869 B-upper_bound
on 29 31 2870 2872 O
the 32 35 2873 2876 O
Eastern 36 43 2877 2884 B-clinical_variable
Cooperative 44 55 2885 2896 I-clinical_variable
Oncology 56 64 2897 2905 I-clinical_variable
Group 65 70 2906 2911 I-clinical_variable
( 71 72 2912 2913 I-clinical_variable
ECOG 72 76 2913 2917 I-clinical_variable
) 76 77 2917 2918 I-clinical_variable
scale 78 83 2919 2924 I-clinical_variable
. 83 84 2924 2925 O
A 85 86 2926 2927 O
performance 87 98 2928 2939 O
status 99 105 2940 2946 O
of 106 108 2947 2949 O
2 109 110 2950 2951 O
on 111 113 2952 2954 O
the 114 117 2955 2958 O
ECOG 118 122 2959 2963 B-clinical_variable
scale 123 128 2964 2969 I-clinical_variable
may 129 132 2970 2973 O
be 133 135 2974 2976 O
entered 136 143 2977 2984 O
upon 144 148 2985 2989 O
the 149 152 2990 2993 O
review 153 159 2994 3000 O
and 160 163 3001 3004 O
approval 164 172 3005 3013 O
of 173 175 3014 3016 O
the 176 179 3017 3020 O
medical 180 187 3021 3028 O
monitor 188 195 3029 3036 O

Pregnant 0 8 3037 3045 B-pregnancy

Previously 0 10 3046 3056 B-treatment
treated 11 18 3057 3064 I-treatment
with 19 23 3065 3069 I-treatment
an 24 26 3070 3072 I-treatment
anti 27 31 3073 3077 I-treatment
- 31 32 3077 3078 I-treatment
DKK-1 32 37 3078 3083 I-treatment
therapy 38 45 3084 3091 I-treatment

Prior 0 5 3092 3097 B-treatment
treatment 6 15 3098 3107 I-treatment
anti- 16 21 3108 3113 I-treatment
programmed 22 32 3114 3124 I-treatment
death-1 33 40 3125 3132 I-treatment
( 41 42 3133 3134 I-treatment
PD-1)/ 42 48 3134 3140 I-treatment
anti 49 53 3141 3145 B-treatment
- 53 54 3145 3146 I-treatment
PD 54 56 3146 3148 I-treatment
- 56 57 3148 3149 I-treatment
ligand 57 63 3149 3155 I-treatment
1 64 65 3156 3157 I-treatment
( 66 67 3158 3159 I-treatment
PD 67 69 3159 3161 I-treatment
- 69 70 3161 3162 I-treatment
L1 70 72 3162 3164 I-treatment
) 72 73 3164 3165 I-treatment
monoclonal 74 84 3166 3176 I-treatment
antibody 85 93 3177 3185 I-treatment
( 94 95 3186 3187 I-treatment
mAb 95 98 3187 3190 I-treatment
) 98 99 3190 3191 I-treatment
is 100 102 3192 3194 O
permitted 103 112 3195 3204 O
in 113 115 3205 3207 O
patients 116 124 3208 3216 O
provided 125 133 3217 3225 O
the 134 137 3226 3229 O
patient 138 145 3230 3237 O
's 145 147 3237 3239 O
disease 148 155 3240 3247 O
is 156 158 3248 3250 O
primary 159 166 3251 3258 O
refractory 167 177 3259 3269 O
, 177 178 3269 3270 O
and 179 182 3271 3274 O
the 183 186 3275 3278 O
patient 187 194 3279 3286 O
is 195 197 3287 3289 O
not 198 201 3290 3293 O
intolerant 202 212 3294 3304 O
of 213 215 3305 3307 O
pembrolizumab 216 229 3308 3321 B-treatment
. 229 230 3321 3322 O
Patients 231 239 3323 3331 O
who 240 243 3332 3335 O
are 244 247 3336 3339 O
not 248 251 3340 3343 O
eligible 252 260 3344 3352 O
to 261 263 3353 3355 O
receive 264 271 3356 3363 O
pembrolizumab 272 285 3364 3377 O
will 286 290 3378 3382 O
be 291 293 3383 3385 O
allowed 294 301 3386 3393 O
to 302 304 3394 3396 O
receive 305 312 3397 3404 O
single 313 319 3405 3411 O
agent 320 325 3412 3417 O
DKN-01 326 332 3418 3424 B-treatment

Prior 0 5 3425 3430 B-treatment
treatment 6 15 3431 3440 I-treatment
with 16 20 3441 3445 I-treatment
paclitaxel 21 31 3446 3456 I-treatment
as 32 34 3457 3459 O
part 35 39 3460 3464 O
of 40 42 3465 3467 O
a 43 44 3468 3469 O
definitive 45 55 3470 3480 B-treatment
therapy 56 63 3481 3488 I-treatment
regimen 64 71 3489 3496 O
is 72 74 3497 3499 O
acceptable 75 85 3500 3510 O
. 85 86 3510 3511 O
Patients 87 95 3512 3520 O
who 96 99 3521 3524 O
are 100 103 3525 3528 O
unable 104 110 3529 3535 O
to 111 113 3536 3538 O
receive 114 121 3539 3546 O
paclitaxel 122 132 3547 3557 O
for 133 136 3558 3561 O
any 137 140 3562 3565 O
reason 141 147 3566 3572 O
will 148 152 3573 3577 O
be 153 155 3578 3580 O
allowed 156 163 3581 3588 O
to 164 166 3589 3591 O
receive 167 174 3592 3599 O
DKN-01 175 181 3600 3606 O
as 182 184 3607 3609 O
a 185 186 3610 3611 O
single 187 193 3612 3618 O
agent 194 199 3619 3624 O

Receipt 0 7 3625 3632 O
of 8 10 3633 3635 O
any 11 14 3636 3639 O
live 15 19 3640 3644 B-treatment
vaccines 20 28 3645 3653 I-treatment
within 29 35 3654 3660 O
30 36 38 3661 3663 B-upper_bound
days 39 43 3664 3668 I-upper_bound
before 44 50 3669 3675 I-upper_bound
the 51 54 3676 3679 O
first 55 60 3680 3685 O
dose 61 65 3686 3690 O
of 66 68 3691 3693 O
study 69 74 3694 3699 B-treatment
treatment 75 84 3700 3709 I-treatment
and 85 88 3710 3713 O
while 89 94 3714 3719 O
participating 95 108 3720 3733 O
in 109 111 3734 3736 O
the 112 115 3737 3740 O
study 116 121 3741 3746 O

Replacement 0 11 3747 3758 B-treatment
therapy 12 19 3759 3766 I-treatment
( 20 21 3767 3768 O
thyroxine 21 30 3768 3777 B-treatment
, 30 31 3777 3778 O
insulin 32 39 3779 3786 B-treatment
, 39 40 3786 3787 O
or 41 43 3788 3790 O
physiologic 44 55 3791 3802 B-treatment
corticosteroid 56 70 3803 3817 I-treatment
replacement 71 82 3818 3829 I-treatment
therapy 83 90 3830 3837 I-treatment
for 91 94 3838 3841 O
adrenal 95 102 3842 3849 B-chronic_disease
or 103 105 3850 3852 I-chronic_disease
pituitary 106 115 3853 3862 I-chronic_disease
insufficiency 116 129 3863 3876 I-chronic_disease
, 129 130 3876 3877 O
etc 131 134 3878 3881 O
. 134 135 3881 3882 O
) 135 136 3882 3883 O
is 137 139 3884 3886 O
not 140 143 3887 3890 O
considered 144 154 3891 3901 O
a 155 156 3902 3903 O
form 157 161 3904 3908 O
of 162 164 3909 3911 O
systemic 165 173 3912 3920 B-treatment
treatment 174 183 3921 3930 I-treatment

Serious 0 7 3931 3938 O
nonmalignant 8 20 3939 3951 B-cancer
disease 21 28 3952 3959 I-cancer

Significant 0 11 3960 3971 O
allergy 12 19 3972 3979 O
to 20 22 3980 3982 O
a 23 24 3983 3984 O
pharmaceutical 25 39 3985 3999 B-allergy_name
therapy 40 47 4000 4007 I-allergy_name
that 48 52 4008 4012 O
, 52 53 4012 4013 O
in 54 56 4014 4016 O
the 57 60 4017 4020 O
opinion 61 68 4021 4028 O
of 69 71 4029 4031 O
the 72 75 4032 4035 O
investigator 76 88 4036 4048 O
, 88 89 4048 4049 O
poses 90 95 4050 4055 O
an 96 98 4056 4058 O
increased 99 108 4059 4068 O
risk 109 113 4069 4073 O
to 114 116 4074 4076 O
the 117 120 4077 4080 O
participant 121 132 4081 4092 O

Systemic 0 8 4093 4101 O
central 9 16 4102 4109 B-cancer
nervous 17 24 4110 4117 I-cancer
system 25 31 4118 4124 I-cancer
( 32 33 4125 4126 I-cancer
CNS 33 36 4126 4129 I-cancer
) 36 37 4129 4130 I-cancer
malignancy 38 48 4131 4141 I-cancer
or 49 51 4142 4144 O
metastasis 52 62 4145 4155 B-cancer

Treatment 0 9 4156 4165 B-treatment
with 10 14 4166 4170 I-treatment
any 15 18 4171 4174 I-treatment
other 19 24 4175 4180 I-treatment
investigational 25 40 4181 4196 I-treatment
agent 41 46 4197 4202 I-treatment
within 47 53 4203 4209 O
30 54 56 4210 4212 B-upper_bound
days 57 61 4213 4217 I-upper_bound
prior 62 67 4218 4223 I-upper_bound
to 68 70 4224 4226 O
study 71 76 4227 4232 O
entry 77 82 4233 4238 O

Treatment 0 9 4239 4248 B-treatment
with 10 14 4249 4253 O
corticosteroids 15 30 4254 4269 B-treatment
( 31 32 4270 4271 O
≥ 32 33 4271 4272 O
10 34 36 4273 4275 B-lower_bound
mg 37 39 4276 4278 I-lower_bound
per 40 43 4279 4282 I-lower_bound
day 44 47 4283 4286 I-lower_bound
prednisone 48 58 4287 4297 O
or 59 61 4298 4300 O
equivalent 62 72 4301 4311 O
) 72 73 4311 4312 O
or 74 76 4313 4315 O
other 77 82 4316 4321 O
immune 83 89 4322 4328 B-treatment
suppressive 90 101 4329 4340 I-treatment
drugs 102 107 4341 4346 I-treatment
within 108 114 4347 4353 O
the 115 118 4354 4357 O
14 119 121 4358 4360 B-upper_bound
days 122 126 4361 4365 I-upper_bound
prior 127 132 4366 4371 I-upper_bound
to 133 135 4372 4374 O
study 136 141 4375 4380 O
entry 142 147 4381 4386 O

Treatment 0 9 4387 4396 B-treatment
with 10 14 4397 4401 O
low 15 18 4402 4405 B-treatment
dose 19 23 4406 4410 I-treatment
chemotherapy 24 36 4411 4423 I-treatment
concurrent 37 47 4424 4434 O
with 48 52 4435 4439 O
radiation 53 62 4440 4449 B-treatment
within 63 69 4450 4456 O
14 70 72 4457 4459 B-upper_bound
days 73 77 4460 4464 I-upper_bound
prior 78 83 4465 4470 I-upper_bound
to 84 86 4471 4473 O
study 87 92 4474 4479 O
entry 93 98 4480 4485 O

Treatment 0 9 4486 4495 B-treatment
with 10 14 4496 4500 I-treatment
radiation 15 24 4501 4510 I-treatment
therapy 25 32 4511 4518 I-treatment
within 33 39 4519 4525 O
14 40 42 4526 4528 B-upper_bound
days 43 47 4529 4533 I-upper_bound
prior 48 53 4534 4539 I-upper_bound
to 54 56 4540 4542 O
study 57 62 4543 4548 O
entry 63 68 4549 4554 O

Treatment 0 9 4555 4564 B-treatment
with 10 14 4565 4569 I-treatment
surgery 15 22 4570 4577 I-treatment
or 23 25 4578 4580 O
chemotherapy 26 38 4581 4593 B-treatment
within 39 45 4594 4600 O
21 46 48 4601 4603 B-upper_bound
days 49 53 4604 4608 I-upper_bound
prior 54 59 4609 4614 I-upper_bound
to 60 62 4615 4617 O
study 63 68 4618 4623 O
entry 69 74 4624 4629 O
( 75 76 4630 4631 O
42 76 78 4631 4633 B-upper_bound
days 79 83 4634 4638 I-upper_bound
for 84 87 4639 4642 O
nitrosoureas 88 100 4643 4655 B-treatment
or 101 103 4656 4658 O
mitomycin 104 113 4659 4668 B-treatment
C 114 115 4669 4670 I-treatment
) 115 116 4670 4671 O

Tumor 0 5 4672 4677 B-cancer
tissue 6 12 4678 4684 O
for 13 16 4685 4688 O
mandatory 17 26 4689 4698 O
evaluation 27 37 4699 4709 O

nursing 0 7 4710 4717 O
women 8 13 4718 4723 B-gender

